326 related articles for article (PubMed ID: 30610952)
1. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis.
Costa C; Moreira JN; Amaral MH; Sousa Lobo JM; Silva AC
J Control Release; 2019 Feb; 295():187-200. PubMed ID: 30610952
[TBL] [Abstract][Full Text] [Related]
2. A review of intranasal formulations for the treatment of seizure emergencies.
Kapoor M; Cloyd JC; Siegel RA
J Control Release; 2016 Sep; 237():147-59. PubMed ID: 27397490
[TBL] [Abstract][Full Text] [Related]
3. Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.
Cunha S; Forbes B; Sousa Lobo JM; Silva AC
Int J Nanomedicine; 2021; 16():4373-4390. PubMed ID: 34234432
[TBL] [Abstract][Full Text] [Related]
4. Superparamagnetic Iron Oxide-Loaded Lipid Nanocarriers Incorporated in Thermosensitive In Situ Gel for Magnetic Brain Targeting of Clonazepam.
Abbas H; Refai H; El Sayed N
J Pharm Sci; 2018 Aug; 107(8):2119-2127. PubMed ID: 29665379
[TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
6. Intranasal delivery of lipid-based nanosystems as a promising approach for brain targeting of the new-generation antiepileptic drug perampanel.
Meirinho S; Rodrigues M; Ferreira CL; Oliveira RC; Fortuna A; Santos AO; Falcão A; Alves G
Int J Pharm; 2022 Jun; 622():121853. PubMed ID: 35623483
[TBL] [Abstract][Full Text] [Related]
7. Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases.
Cunha S; Almeida H; Amaral MH; Lobo JMS; Silva AC
Curr Pharm Des; 2017 Nov; ():. PubMed ID: 29189138
[TBL] [Abstract][Full Text] [Related]
8. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of
Costa CP; Moreira JN; Sousa Lobo JM; Silva AC
Acta Pharm Sin B; 2021 Apr; 11(4):925-940. PubMed ID: 33996407
[TBL] [Abstract][Full Text] [Related]
9. Lipid Nanoparticles for Nasal/Intranasal Drug Delivery.
Cunha S; Amaral MH; Lobo JMS; Silva AC
Crit Rev Ther Drug Carrier Syst; 2017; 34(3):257-282. PubMed ID: 28845761
[TBL] [Abstract][Full Text] [Related]
10. QbD-driven development of intranasal lipid nanoparticles for depression treatment.
Vitorino C; Silva S; Gouveia F; Bicker J; Falcão A; Fortuna A
Eur J Pharm Biopharm; 2020 Aug; 153():106-120. PubMed ID: 32525033
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Intranasal Administration for Brain-Targeting Delivery: A Comprehensive Review of Lipid-Based Nanoparticles and Stimuli-Responsive Gel Formulations.
Koo J; Lim C; Oh KT
Int J Nanomedicine; 2024; 19():1767-1807. PubMed ID: 38414526
[TBL] [Abstract][Full Text] [Related]
12. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease.
Akel H; Ismail R; Csóka I
Eur J Pharm Biopharm; 2020 Mar; 148():38-53. PubMed ID: 31926222
[TBL] [Abstract][Full Text] [Related]
13. Intranasal clobazam delivery in the treatment of status epilepticus.
Florence K; Manisha L; Kumar BA; Ankur K; Kumar MA; Ambikanandan M
J Pharm Sci; 2011 Feb; 100(2):692-703. PubMed ID: 20799366
[TBL] [Abstract][Full Text] [Related]
14. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents.
Musumeci T; Serapide MF; Pellitteri R; Dalpiaz A; Ferraro L; Dal Magro R; Bonaccorso A; Carbone C; Veiga F; Sancini G; Puglisi G
Eur J Pharm Biopharm; 2018 Dec; 133():309-320. PubMed ID: 30399400
[TBL] [Abstract][Full Text] [Related]
15. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
[TBL] [Abstract][Full Text] [Related]
16. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting.
Selvaraj K; Gowthamarajan K; Karri VVSR
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2088-2095. PubMed ID: 29282995
[TBL] [Abstract][Full Text] [Related]
17. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.
Eskandari S; Varshosaz J; Minaiyan M; Tabbakhian M
Int J Nanomedicine; 2011; 6():363-71. PubMed ID: 21499426
[TBL] [Abstract][Full Text] [Related]
18. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies.
Pires PC; Santos AO
J Control Release; 2018 Jan; 270():89-100. PubMed ID: 29199063
[TBL] [Abstract][Full Text] [Related]
19. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
20. Enhancing Curcumin Oral Bioavailability Through Nanoformulations.
Ipar VS; Dsouza A; Devarajan PV
Eur J Drug Metab Pharmacokinet; 2019 Aug; 44(4):459-480. PubMed ID: 30771095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
